# Bovine Adenoviral Vector-Based Platform for Vaccine Development

## TL;DR

This paper explores the use of bovine adenovirus type 3 as a promising platform for developing next-generation vaccines.

## Contribution

The paper introduces bovine AdV-3 as a novel vector platform that avoids preexisting immunity and offers high efficiency and safety.

## Key findings

- BAdV-3 vectors elude preexisting HAdV-specific immune responses.
- BAdV-3 has high transduction efficiency and large transgene insertion capacity.
- BAdV-3 is low in pathogenicity and safe for use as a vaccine platform.

## Abstract

Adenoviral (AdV) vector-based vaccines employing the human AdV (HAdV) and chimpanzee AdV (ChAdV) vector platforms played a crucial role in combating the COVID-19 pandemic. However, the widespread use of these platforms, the prevalence of various HAdV types, and the resulting preexisting immunity have significantly impacted the vaccines utilizing these vector platforms. Considering these challenges, the bovine AdV type 3 (BAdV-3) vector system has emerged as a versatile and innovative platform for developing next-generation vaccines against infectious diseases. Inherent attributes like a high transduction efficiency, large transgene insertion capacity, broad tissue tropism, and robust induction of innate immunity add significant value to the BAdV vector platform for vaccine design. BAdV-3 vectors effectively elude HAdV-specific preexisting humoral and cellular immune responses. Additionally, BAdV-3 is low in pathogenicity for its host and is anticipated to be safe as a vaccine platform. This systematic review provides an overview of the development of BAdV-3 as a vaccine delivery platform and its application in designing vaccines for infectious agents of human and veterinary importance.